The Aging Adipose Organ: Lipid Redistribution, Inflammation, and Cellular Senescence

  • Michael B. Stout
  • Tamara Tchkonia
  • James L. KirklandEmail author
Part of the Nutrition and Health book series (NH)


White adipose tissue (WAT) is an immensely plastic organ that plays a vital role in regulating metabolic homeostasis and systemic inflammation. Advancing age mitigates the dynamic nature of WAT which promotes the manifestation of several lipodystrophic-associated comorbidities. Inflammation and the accumulation of senescence cells likely play a key role in this process by inhibiting adipogenesis. The reduction of WAT functional capacity with aging and the role that inflammation and cellular senescence may play in this process will be explored throughout this review.


Aging Cellular senescence Inflammation White adipose tissue 



This work was supported by NIH grants AG13925 (JLK), AG31736 (A. Bartke), and AG41122 (JLK), the Robert and Arlene Kogod Center on Aging, and the Noaber, Glenn, and Ellison Foundations.


  1. 1.
    Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444(7121):847–53.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21(6):697–738.PubMedGoogle Scholar
  3. 3.
    Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–89.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Fox CS, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39–48.PubMedGoogle Scholar
  5. 5.
    Klein S, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America’s health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007;30(6):1647–52.PubMedGoogle Scholar
  6. 6.
    Morley JE. The metabolic syndrome and aging. J Gerontol A Biol Sci Med Sci. 2004;59(2):139–42.PubMedGoogle Scholar
  7. 7.
    Morley JE, Sinclair A. The metabolic syndrome in older persons: a loosely defined constellation of symptoms or a distinct entity? Age Ageing. 2009;38(5):494–7.PubMedGoogle Scholar
  8. 8.
    Cartwright MJ, Tchkonia T, Kirkland JL. Aging in adipocytes: potential impact of inherent, depot-specific mechanisms. Exp Gerontol. 2007;42(6):463–71.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Kotani K, et al. Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. Int J Obes Relat Metab Disord. 1994;18(4):207–12.PubMedGoogle Scholar
  10. 10.
    Kuk JL, et al. Age-related changes in total and regional fat distribution. Ageing Res Rev. 2009;8(4):339–48.PubMedGoogle Scholar
  11. 11.
    Matsuzawa Y, et al. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res. 1995;3 Suppl 2:187S–94.PubMedGoogle Scholar
  12. 12.
    Raguso CA, et al. A 3-year longitudinal study on body composition changes in the elderly: role of physical exercise. Clin Nutr. 2006;25(4):573–80.PubMedGoogle Scholar
  13. 13.
    Baker DJ, et al. Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J Cell Biol. 2006;172(4):529–40.PubMedCentralPubMedGoogle Scholar
  14. 14.
    DeNino WF, et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care. 2001;24(5):925–32.PubMedGoogle Scholar
  15. 15.
    Hughes VA, et al. Anthropometric assessment of 10-y changes in body composition in the elderly. Am J Clin Nutr. 2004;80(2):475–82.PubMedGoogle Scholar
  16. 16.
    Goodpaster BH, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med. 2005;165(7):777–83.PubMedGoogle Scholar
  17. 17.
    Goodpaster BH, et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care. 2003;26(2):372–9.PubMedGoogle Scholar
  18. 18.
    Fontana L, Klein S. Aging, adiposity, and calorie restriction. JAMA. 2007;297(9):986–94.PubMedGoogle Scholar
  19. 19.
    Thompson D, et al. Physical activity and exercise in the regulation of human adipose tissue physiology. Physiol Rev. 2012;92(1):157–91.PubMedGoogle Scholar
  20. 20.
    Bays HE, et al. Adiposopathy and bariatric surgery: is ‘sick fat’ a surgical disease? Int J Clin Pract. 2009;63(9):1285–300.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Barzilai N, Gupta G. Revisiting the role of fat mass in the life extension induced by caloric restriction. J Gerontol A Biol Sci Med Sci. 1999;54(3):B89–96. discussion B97–8.PubMedGoogle Scholar
  22. 22.
    Chang GR, et al. Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. J Pharmacol Sci. 2009;109(4):496–503.PubMedGoogle Scholar
  23. 23.
    Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392–5.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Berryman DE, et al. Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res. 2008;18(6):455–71.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003;299(5606):572–4.PubMedGoogle Scholar
  26. 26.
    Selman C, et al. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 2008;22(3):807–18.PubMedGoogle Scholar
  27. 27.
    Selman C, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009;326(5949):140–4.PubMedGoogle Scholar
  28. 28.
    Um SH, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431(7005):200–5.PubMedGoogle Scholar
  29. 29.
    Koutsari C, et al. Fatty acid metabolism in the elderly: effects of dehydroepiandrosterone and testosterone replacement in hormonally deficient men and women. J Clin Endocrinol Metab. 2009;94(9):3414–23.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Tchkonia T, et al. Fat tissue, aging, and cellular senescence. Aging Cell. 2010;9(5):667–84.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Baker DJ, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232–6.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Garg A. Clinical review#: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313–25.PubMedGoogle Scholar
  33. 33.
    Cinti S. Transdifferentiation properties of adipocytes in the adipose organ. Am J Physiol Endocrinol Metab. 2009;297(5):E977–86.PubMedGoogle Scholar
  34. 34.
    Van Harmelen V, Rohrig K, Hauner H. Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. Metab Clin Exp. 2004;53(5):632–7.PubMedGoogle Scholar
  35. 35.
    Karagiannides I, et al. Altered expression of C/EBP family members results in decreased adipogenesis with aging. Am J Physiol Regul Integr Comp Physiol. 2001;280(6):R1772–80.PubMedGoogle Scholar
  36. 36.
    Kirkland JL, Hollenberg CH, Gillon WS. Age, anatomic site, and the replication and differentiation of adipocyte precursors. Am J Physiol. 1990;258(2 Pt 1):C206–10.PubMedGoogle Scholar
  37. 37.
    Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74(4):761–811.PubMedGoogle Scholar
  38. 38.
    Bays HE, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6(3):343–68.PubMedGoogle Scholar
  39. 39.
    Rebuffe-Scrive M, et al. Muscle and adipose tissue morphology and metabolism in Cushing’s syndrome. J Clin Endocrinol Metab. 1988;67(6):1122–8.PubMedGoogle Scholar
  40. 40.
    Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther. 2005;3(3):393–404.PubMedGoogle Scholar
  41. 41.
    Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord. 2004;28 Suppl 4:S12–21.PubMedGoogle Scholar
  42. 42.
    Ravussin E, et al. Lipids and insulin resistance: what we’ve learned at the Fourth International Smolenice Symposium. Ann N Y Acad Sci. 2002;967:576–80.PubMedGoogle Scholar
  43. 43.
    Karagiannides I, et al. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci U S A. 2006;103(13):5207–12.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Uzunkoy A, Ozbilge H, Horoz M. The influence of omentectomy on bacterial clearance: an experimental study. TJTES. 2009;15(6):541–5.PubMedGoogle Scholar
  45. 45.
    Schaffler A, Scholmerich J, Salzberger B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 2007;28(9):393–9.PubMedGoogle Scholar
  46. 46.
    Ouchi N, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83(3):847–50.PubMedGoogle Scholar
  48. 48.
    Samaras K, et al. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity. 2010;18(5):884–9.PubMedGoogle Scholar
  49. 49.
    Dolinkova M, et al. The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. Mol Cell Endocrinol. 2008;291(1–2):63–70.PubMedGoogle Scholar
  50. 50.
    Kloting N, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007;6(1):79–87.PubMedGoogle Scholar
  51. 51.
    Morin CL, et al. Adipose tissue-derived tumor necrosis factor-alpha activity is elevated in older rats. J Gerontol A Biol Sci Med Sci. 1997;52(4):B190–5.PubMedGoogle Scholar
  52. 52.
    Starr ME, Evers BM, Saito H. Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6. J Gerontol A Biol Sci Med Sci. 2009;64(7):723–30.PubMedGoogle Scholar
  53. 53.
    Wu D, et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J Immunol. 2007;179(7):4829–39.PubMedGoogle Scholar
  54. 54.
    Tang W, et al. White fat progenitor cells reside in the adipose vasculature. Science. 2008;322(5901):583–6.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Tran KV, et al. The vascular endothelium of the adipose tissue gives rise to both white and brown fat cells. Cell Metab. 2012;15(2):222–9.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Crossno Jr JT, et al. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J Clin Invest. 2006;116(12):3220–8.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Hong KM, et al. Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. FASEB J. 2005;19(14):2029–31.PubMedGoogle Scholar
  58. 58.
    Tchkonia T, et al. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am J Physiol Regul Integr Comp Physiol. 2002;282(5):R1286–96.PubMedGoogle Scholar
  59. 59.
    Tchkonia T, et al. Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes. 2006;55(9):2571–8.PubMedGoogle Scholar
  60. 60.
    Tchkonia T, et al. Different fat depots are distinct mini-organs. Curr Opin Endocrinol Diabetes Obes. 2001;8(5):227–34.Google Scholar
  61. 61.
    Tchkonia T, et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am J Physiol Endocrinol Metab. 2007;292(1):E298–307.PubMedGoogle Scholar
  62. 62.
    Yamamoto Y, et al. Adipose depots possess unique developmental gene signatures. Obesity. 2010;18(5):872–8.PubMedGoogle Scholar
  63. 63.
    Koppen A, Kalkhoven E. Brown vs white adipocytes: the PPAR gamma coregulator story. FEBS Lett. 2010;584(15):3250–9.PubMedGoogle Scholar
  64. 64.
    Gearing KL, et al. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A. 1993;90(4):1440–4.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Issemann I, et al. The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. Biochimie. 1993;75(3–4):251–6.PubMedGoogle Scholar
  66. 66.
    Zhu Y, et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci U S A. 1995;92(17):7921–5.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Morrison RF, Farmer SR. Role of PPAR gamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis. J Biol Chem. 1999;274(24):17088–97.PubMedGoogle Scholar
  68. 68.
    Lehrke M, Lazar MA. The many faces of PPAR gamma. Cell. 2005;123(6):993–9.PubMedGoogle Scholar
  69. 69.
    Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006;4(4):263–73.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Salma N, Xiao H, Imbalzano AN. Temporal recruitment of CCAAT/enhancer-binding proteins to early and late adipogenic promoters in vivo. J Mol Endocrinol. 2006;36(1):139–51.PubMedGoogle Scholar
  71. 71.
    Rosen ED, et al. C/EBP alpha induces adipogenesis through PPAR gamma: a unified pathway. Genes Dev. 2002;16(1):22–6.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Wu Z, et al. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell. 1999;3(2):151–8.PubMedGoogle Scholar
  73. 73.
    Kirkland JL, et al. Effects of age and anatomic site on preadipocyte number in rat fat depots. J Gerontol. 1994;49(1):B31–5.PubMedGoogle Scholar
  74. 74.
    Charriere G, et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278(11):9850–5.PubMedGoogle Scholar
  75. 75.
    Chung S, et al. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology. 2006;147(11):5340–51.PubMedGoogle Scholar
  76. 76.
    Lin Y, et al. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem. 2000;275(32):24255–63.PubMedGoogle Scholar
  77. 77.
    Vitseva OI, et al. Inducible Toll-like receptor and NF-kappaB regulatory pathway expression in human adipose tissue. Obesity. 2008;16(5):932–7.PubMedCentralPubMedGoogle Scholar
  78. 78.
    Gustafson B, et al. Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am J Physiol Endocrinol Metab. 2009;297(5):E999–1003.PubMedGoogle Scholar
  79. 79.
    Isakson P, et al. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes. 2009;58(7):1550–7.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Mack I, et al. Functional analyses reveal the greater potency of preadipocytes compared with adipocytes as endothelial cell activator under normoxia, hypoxia, and TNFalpha exposure. Am J Physiol Endocrinol Metab. 2009;297(3):E735–48.PubMedGoogle Scholar
  81. 81.
    Cousin B, et al. A role for preadipocytes as macrophage-like cells. FASEB J. 1999;13(2):305–12.PubMedGoogle Scholar
  82. 82.
    Kirkland JL, Hollenberg CH. Inhibitors of preadipocyte replication: opportunities for the treatment of obesity. Prog Mol Subcell Biol. 1998;20:177–95.PubMedGoogle Scholar
  83. 83.
    Schipper BM, et al. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann Plast Surg. 2008;60(5):538–44.PubMedGoogle Scholar
  84. 84.
    Karagiannides I, et al. Increased CUG triplet repeat-binding protein-1 predisposes to impaired adipogenesis with aging. J Biol Chem. 2006;281(32):23025–33.PubMedGoogle Scholar
  85. 85.
    Cartwright MJ, et al. Aging, depot origin, and preadipocyte gene expression. J Gerontol A Biol Sci Med Sci. 2010;65(3):242–51.PubMedGoogle Scholar
  86. 86.
    Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30.PubMedCentralPubMedGoogle Scholar
  87. 87.
    Visser M, et al. One- and two-year change in body composition as measured by DXA in a population-based cohort of older men and women. J Appl Physiol. 2003;94(6):2368–74.PubMedGoogle Scholar
  88. 88.
    Kyle UG, et al. Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. Eur J Clin Nutr. 2001;55(8):663–72.PubMedGoogle Scholar
  89. 89.
    Rabkin SW. Epicardial fat: properties, function and relationship to obesity. Obes Rev. 2007;8(3):253–61.PubMedGoogle Scholar
  90. 90.
    Slawik M, Vidal-Puig AJ. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev. 2006;5(2):144–64.PubMedGoogle Scholar
  91. 91.
    Pouliot MC, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73(7):460–8.PubMedGoogle Scholar
  92. 92.
    Barzilai N, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 1999;48(1):94–8.PubMedGoogle Scholar
  93. 93.
    Gabriely I, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes. 2002;51(10):2951–8.PubMedGoogle Scholar
  94. 94.
    Kim YW, Kim JY, Lee SK. Surgical removal of visceral fat decreases plasma free fatty acid and increases insulin sensitivity on liver and peripheral tissue in monosodium glutamate (MSG)-obese rats. J Korean Med Sci. 1999;14(5):539–45.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Dunn JP, et al. Hepatic and peripheral insulin sensitivity and diabetes remission at 1 month after Roux-en-Y gastric bypass surgery in patients randomized to omentectomy. Diabetes Care. 2012;35(1):137–42.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Fabbrini E, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010;139(2):448–55.PubMedCentralPubMedGoogle Scholar
  97. 97.
    Klein S. Is visceral fat responsible for the metabolic abnormalities associated with obesity?: implications of omentectomy. Diabetes Care. 2010;33(7):1693–4.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Koster A, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity. 2010;18(12):2354–61.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Caserta F, et al. Fat depot origin affects fatty acid handling in cultured rat and human preadipocytes. Am J Physiol Endocrinol Metab. 2001;280(2):E238–47.PubMedGoogle Scholar
  100. 100.
    Djian P, Roncari AK, Hollenberg CH. Influence of anatomic site and age on the replication and differentiation of rat adipocyte precursors in culture. J Clin Invest. 1983;72(4):1200–8.PubMedCentralPubMedGoogle Scholar
  101. 101.
    Kirkland JL, Hollenberg CH, Gillon WS. Ageing, differentiation, and gene expression in rat epididymal preadipocytes. Biochem Cell Biol. 1993;71(11–12):556–61.PubMedGoogle Scholar
  102. 102.
    Tchkonia T, et al. Increased TNFalpha and CCAAT/enhancer-binding protein homologous protein with aging predispose preadipocytes to resist adipogenesis. Am J Physiol Endocrinol Metab. 2007;293(6):E1810–9.PubMedGoogle Scholar
  103. 103.
    Wang H, Kirkland JL, Hollenberg CH. Varying capacities for replication of rat adipocyte precursor clones and adipose tissue growth. J Clin Invest. 1989;83(5):1741–6.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Hotta K, et al. Age-related adipose tissue mRNA expression of ADD1/SREBP1, PPAR gamma, lipoprotein lipase, and GLUT4 glucose transporter in rhesus monkeys. J Gerontol A Biol Sci Med Sci. 1999;54(5):B183–8.PubMedGoogle Scholar
  105. 105.
    Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev. 1992;6(3):439–53.PubMedGoogle Scholar
  106. 106.
    Ikeyama S, et al. Expression of the pro-apoptotic gene gadd153/chop is elevated in liver with aging and sensitizes cells to oxidant injury. J Biol Chem. 2003;278(19):16726–31.PubMedGoogle Scholar
  107. 107.
    Timchenko NA, et al. CUG repeat binding protein (CUGBP1) interacts with the 5′ region of C/EBP beta mRNA and regulates translation of C/EBP beta isoforms. Nucleic Acids Res. 1999;27(22):4517–25.PubMedCentralPubMedGoogle Scholar
  108. 108.
    Jundt F, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005;106(5):1801–7.PubMedGoogle Scholar
  109. 109.
    van der Sanden MH, et al. Inhibition of phosphatidylcholine synthesis induces expression of the endoplasmic reticulum stress and apoptosis-related protein CCAAT/enhancer-binding protein-homologous protein (CHOP/GADD153). Biochem J. 2003;369(Pt 3):643–50.PubMedCentralPubMedGoogle Scholar
  110. 110.
    Wang XZ, et al. Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol. 1996;16(8):4273–80.PubMedCentralPubMedGoogle Scholar
  111. 111.
    Harris TB, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506–12.PubMedGoogle Scholar
  112. 112.
    Minamino T, et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med. 2009;15(9):1082–7.PubMedGoogle Scholar
  113. 113.
    Beausejour CM, Campisi J. Ageing: balancing regeneration and cancer. Nature. 2006;443(7110):404–5.PubMedGoogle Scholar
  114. 114.
    Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.PubMedGoogle Scholar
  115. 115.
    Jeyapalan JC, Sedivy JM. Cellular senescence and organismal aging. Mech Ageing Dev. 2008;129(7–8):467–74.PubMedCentralPubMedGoogle Scholar
  116. 116.
    Narita M, Lowe SW. Senescence comes of age. Nat Med. 2005;11(9):920–2.PubMedGoogle Scholar
  117. 117.
    Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120(4):513–22.PubMedGoogle Scholar
  118. 118.
    Martin-Ruiz C, et al. Stochastic variation in telomere shortening rate causes heterogeneity of human fibroblast replicative life span. J Biol Chem. 2004;279(17):17826–33.PubMedGoogle Scholar
  119. 119.
    Narita M, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113(6):703–16.PubMedGoogle Scholar
  120. 120.
    Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? Cell. 2000;102(4):407–10.PubMedGoogle Scholar
  121. 121.
    Campisi J. Cancer, aging and cellular senescence. In Vivo. 2000;14(1):183–8.PubMedGoogle Scholar
  122. 122.
    Campisi J. Fragile fugue: p53 in aging, cancer and IGF signaling. Nat Med. 2004;10(3):231–2.PubMedGoogle Scholar
  123. 123.
    Xue W, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656–60.PubMedGoogle Scholar
  124. 124.
    Lee BY, et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. 2006;5(2):187–95.PubMedGoogle Scholar
  125. 125.
    Wang C, et al. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell. 2009;8(3):311–23.PubMedGoogle Scholar
  126. 126.
    Coppe JP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853–68.PubMedGoogle Scholar
  127. 127.
    Freund A, et al. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med. 2010;16(5):238–46.PubMedCentralPubMedGoogle Scholar
  128. 128.
    Parrinello S, et al. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005;118(Pt 3):485–96.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Michael B. Stout
    • 1
  • Tamara Tchkonia
    • 1
  • James L. Kirkland
    • 1
    Email author
  1. 1.Mayo ClinicRobert & Arlene Kogod Center on AgingRochesterUSA

Personalised recommendations